| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/HEC.1181 |
| P698 | PubMed publication ID | 17039573 |
| P50 | author | Werner Brouwer | Q57418012 |
| G. Ardine de Wit | Q60669638 | ||
| Rudolf T. Hoogenveen | Q130271232 | ||
| Talitha L. Feenstra | Q48524527 | ||
| Pieter M van Baal | Q57008929 | ||
| P2860 | cites work | Cost-effectiveness analysis and capital costs | Q57345505 |
| Does prevention save costs? | Q61249003 | ||
| Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty | Q62381857 | ||
| Cost-effectiveness analysis and health care resource allocation: decision rules under variable returns to scale | Q64133890 | ||
| Stochastic league tables: communicating cost-effectiveness results to decision-makers | Q74245483 | ||
| Colorectal cancer screening: efficiency and effectiveness | Q74440654 | ||
| Economic foundations of cost-effectiveness analysis | Q77105376 | ||
| Theoretical issues in cost-effectiveness analysis | Q77105383 | ||
| A longitudinal study of the effects of age and time to death on hospital costs | Q79774683 | ||
| Should the consumption of survivors be included as a cost in cost-utility analysis? | Q80051928 | ||
| Using epidemiological data to model efficiency in reducing the burden of depression* | Q30689208 | ||
| Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? | Q33550791 | ||
| Need for differential discounting of costs and health effects in cost effectiveness analyses | Q33920490 | ||
| The health care costs of smoking | Q34065264 | ||
| Disability weights for comorbidity and their influence on health-adjusted life expectancy | Q34872562 | ||
| Preventing fatal diseases increases healthcare costs: cause elimination life table approach | Q37149934 | ||
| Modeling the future burden of stroke in The Netherlands: impact of aging, smoking, and hypertension. | Q40407462 | ||
| Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study | Q40424808 | ||
| The cost-effectiveness of the English smoking treatment services: evidence from practice | Q40428943 | ||
| Illustrating the impact of including future costs in economic evaluations: an application to end-stage renal disease care. | Q40551557 | ||
| Future burden and costs of smoking-related disease in the Netherlands: a dynamic modeling approach | Q40574868 | ||
| The impact of aging and smoking on the future burden of chronic obstructive pulmonary disease: a model analysis in the Netherlands | Q40689803 | ||
| QALY league tables: handle with care | Q40794770 | ||
| Accounting for future costs in medical cost-effectiveness analysis | Q40907132 | ||
| Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). | Q46440924 | ||
| Production gains from health care: what should be included in cost-effectiveness analyses? | Q47623036 | ||
| A national burden of disease calculation: Dutch disability-adjusted life-years. Dutch Burden of Disease Group. | Q51975016 | ||
| Statistical inference for cost-effectiveness ratios. | Q52265200 | ||
| A dollar is a dollar is a dollar--or is it? | Q53227404 | ||
| Critical ratios and efficient allocation | Q56503149 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | health policy | Q1519812 |
| prevention | Q1717246 | ||
| P304 | page(s) | 421-433 | |
| P577 | publication date | 2007-04-01 | |
| P1433 | published in | Health Economics | Q15679024 |
| P1476 | title | Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio | |
| P478 | volume | 16 |
| Q93053287 | Analysis of Anesthesia Methods in Percutaneous Kyphoplasty for Treatment of Vertebral Compression Fractures |
| Q33394844 | Cost of illness and disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157. |
| Q33455849 | Cost-effectiveness of an opportunistic screening programme and brief intervention for excessive alcohol use in primary care |
| Q36390484 | Cost-effectiveness of counseling and pedometer use to increase physical activity in the Netherlands: a modeling study |
| Q33770144 | Cost-effectiveness of interventions to promote fruit and vegetable consumption |
| Q37269534 | Cost-effectiveness of lifestyle modification in diabetic patients |
| Q36494908 | Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation. |
| Q50549440 | Economic evaluation and the postponement of health care costs. |
| Q36127370 | Economic evaluation of health promotion for older people-methodological problems and challenges. |
| Q55286885 | Economic evaluation of health promotion interventions for older people: do applied economic studies meet the methodological challenges? |
| Q37519624 | Estimating the short-term clinical and economic benefits of smoking cessation: do we have it right? |
| Q46624604 | Ethical objections against including life-extension costs in cost-effectiveness analysis: a consistent approach |
| Q43710766 | Exploring the influence of proximity to death on disease-specific hospital expenditures: a carpaccio of red herrings. |
| Q93362263 | Future Costs in Cost-Effectiveness Analyses: Past, Present, Future |
| Q39929920 | Healthcare costs and obesity prevention: drug costs and other sector-specific consequences |
| Q38367421 | Incorporation of future costs in health economic analysis publications: current situation and recommendations for the future |
| Q47137261 | Is it Beneficial to Reuse the Balloon in Percutaneous Kyphoplasty for the Treatment of Non-Neoplastic Vertebral Compression Fractures? |
| Q39956669 | Lifestyle intervention: from cost savings to value for money. |
| Q21144656 | Lifetime medical costs of obesity: prevention no cure for increasing health expenditure |
| Q34459873 | Long-term health outcomes and cost-effectiveness of a computer-tailored physical activity intervention among people aged over fifty: modelling the results of a randomized controlled trial |
| Q53062607 | Measurement of QALYS and the welfare implications of survivor consumption and leisure forgone. |
| Q44084668 | Pharmacoeconomic guidelines should prescribe inclusion of indirect medical costs! A response to Grima et Al. |
| Q89161204 | Single balloon versus double balloon bipedicular kyphoplasty: a systematic review and meta-analysis |
| Q31088945 | Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening |
| Q39801542 | Standardizing the inclusion of indirect medical costs in economic evaluations |
| Q35431592 | Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention |
| Q36821473 | The economics of primary prevention of cardiovascular disease - a systematic review of economic evaluations |
| Q83548092 | The evaluation of lifestyle interventions in the Netherlands |
| Q37177887 | The impact of healthcare costs in the last year of life and in all life years gained on the cost-effectiveness of cancer screening |
| Q37976483 | The long-term cost-effectiveness of obesity prevention interventions: systematic literature review |
| Q38610648 | The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncology |
| Q47753545 | Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. |
| Q37269339 | Unrelated medical costs in life-years gained: should they be included in economic evaluations of healthcare interventions? |
| Q49990722 | Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery Disease. |
| Q39609247 | You Only Die Once: Accounting for Multi-Attributable Mortality Risks in Multi-Disease Models for Health-Economic Analyses |
| Q80526348 | [Economic aspects of prevention] |
Search more.